title: Botulinum toxin type B for treatment of spasmodic dysphonia: a case report.
abstract: Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.
authors.affiliation: Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Phillyent.com
authors.forename: Robert Thayer
authors.initials: RT
authors.lastname: Sataloff
authors.forename: Yolanda D
authors.initials: YD
authors.lastname: Heman-Ackah
authors.forename: Lance L
authors.initials: LL
authors.lastname: Simpson
authors.forename: Jong-Beak
authors.initials: JB
authors.lastname: Park
authors.forename: Amy
authors.initials: A
authors.lastname: Zwislewski
authors.forename: Caren
authors.initials: C
authors.lastname: Sokolow
authors.forename: Steven
authors.initials: S
authors.lastname: Mandel
mesh_terms: D001905:Botulinum Toxins / Q000008:administration & dosage / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010608:Pharyngeal Diseases / Q000188:drug therapy / Q000503:physiopathology; D014832:Voice Disorders / Q000188:drug therapy*
chemical_list: C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A